Immunomedics Announces Pricing of Public Offering of Common Stock
13. Juni 2018 08:00 ET
|
Immunomedics, Inc.
MORRIS PLAINS, N.J., June 13, 2018 (GLOBE NEWSWIRE) -- Immunomedics, Inc. (NASDAQ:IMMU) (“Immunomedics” or the “Company”), a leading biopharmaceutical company in the area of antibody-drug conjugates...
Immunomedics Announces Proposed Public Offering of Common Stock
11. Juni 2018 16:13 ET
|
Immunomedics, Inc.
MORRIS PLAINS, N.J., June 11, 2018 (GLOBE NEWSWIRE) -- Immunomedics, Inc. (NASDAQ:IMMU) (“Immunomedics” or the “Company”), a leading biopharmaceutical company in the area of antibody-drug conjugates...
Immunomedics Provides Business Update at the ASCO 2018 Investor Event
04. Juni 2018 08:00 ET
|
Immunomedics, Inc.
CHICAGO, June 04, 2018 (GLOBE NEWSWIRE) -- Immunomedics, Inc., (NASDAQ:IMMU) (“Immunomedics” or the “Company”), a leading biopharmaceutical company in the area of antibody-drug conjugates (ADC),...
Clovis Oncology and Immunomedics Announce Planned Clinical Collaboration to Study Combination Therapies in Metastatic Triple-Negative Breast and Urothelial Cancers
03. Juni 2018 20:00 ET
|
Immunomedics, Inc.
Companies to Start Phase 1/2 Study to Evaluate the Combination of Rubraca® (Rucaparib) and Sacituzumab Govitecan in Patients with Metastatic Triple-negative Breast Cancer and Metastatic Urothelial...
Immunomedics Reveals Promising Data for Sacituzumab Govitecan in Patients Heavily Pretreated for Metastatic Estrogen Receptor-Positive Breast Cancer
03. Juni 2018 10:15 ET
|
Immunomedics, Inc.
Confirmed Overall Response Rate of 31 Percent; with Median Duration of Response of 7.4 Months and Median Progression-free Survival of 6.8 Months CHICAGO, June 03, 2018 (GLOBE NEWSWIRE) --...
Immunomedics Announces Pivotal Study of Sacituzumab Govitecan in Patients With Locally Advanced or Metastatic Urothelial Cancer
01. Juni 2018 08:00 ET
|
Immunomedics, Inc.
MORRIS PLAINS, N.J., June 01, 2018 (GLOBE NEWSWIRE) -- Immunomedics, Inc. (NASDAQ:IMMU) (“Immunomedics” or the “Company”), a leading biopharmaceutical company in the area of antibody-drug conjugates...
Immunomedics to Present at Jefferies 2018 Global Healthcare Conference
30. Mai 2018 08:00 ET
|
Immunomedics, Inc.
MORRIS PLAINS, N.J., May 30, 2018 (GLOBE NEWSWIRE) -- Immunomedics, Inc. (NASDAQ:IMMU) (“Immunomedics” or the “Company”), a science-based and innovation-focused biopharmaceutical company committed...
Immunomedics Submits Biologics License Application For Sacituzumab Govitecan To The U.S. Food and Drug Administration
21. Mai 2018 08:00 ET
|
Immunomedics, Inc.
MORRIS PLAINS, N.J., May 21, 2018 (GLOBE NEWSWIRE) -- Immunomedics, Inc., (NASDAQ:IMMU) (“Immunomedics” or the “Company”), a science-based and innovation-focused biopharmaceutical company committed...
Immunomedics Announces Promising Data of Sacituzumab Govitecan in Estrogen Receptor-Positive Metastatic Breast Cancer
16. Mai 2018 17:01 ET
|
Immunomedics, Inc.
Sacituzumab Govitecan Produced Overall Response Rate of 31 Percent in Patients Post Endocrine Treatment with a Manageable Safety Profile Full Data will be Reported in Oral Presentation at 2018...
Immunomedics Announces Third Quarter Fiscal 2018 Results and Provides Corporate Update
09. Mai 2018 16:00 ET
|
Immunomedics, Inc.
Biologics License Application (BLA) Remains on Track to be Submitted by the End of May 2018 Leadership Team Expanded with Appointment of Dr. Robert Iannone, Head of Research & Development and...